Peter Lawson
Stock Analyst at Barclays
(2.15)
# 1,259
Out of 4,657 analysts
97
Total ratings
41.56%
Success rate
-4.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Maintains: Equal-Weight | $9 → $11 | $6.53 | +68.45% | 4 | Oct 30, 2024 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $25 → $29 | $15.70 | +84.71% | 6 | Oct 25, 2024 | |
| RVMD Revolution Medicines | Maintains: Overweight | $54 → $60 | $55.13 | +8.83% | 3 | Sep 27, 2024 | |
| RLAY Relay Therapeutics | Maintains: Overweight | $14 → $17 | $5.11 | +233.01% | 5 | Sep 10, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $32 → $33 | $15.83 | +108.46% | 4 | Aug 15, 2024 | |
| EXAI Exscientia | Downgrades: Equal-Weight | $5 | $4.69 | +6.61% | 4 | Aug 13, 2024 | |
| IMCR Immunocore Holdings | Maintains: Overweight | $92 → $66 | $31.59 | +108.93% | 2 | Aug 9, 2024 | |
| MGNX MacroGenics | Maintains: Overweight | $9 → $8 | $3.57 | +124.09% | 8 | Jul 31, 2024 | |
| ARVN Arvinas | Maintains: Overweight | $60 → $48 | $22.48 | +113.52% | 6 | Jul 31, 2024 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $75 → $105 | $88.69 | +18.39% | 10 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $22.92 | +35.25% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $10.80 | +57.41% | 3 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $3.85 | +237.66% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $25 | $34.45 | -27.43% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $9 | $4.41 | +104.08% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $22 | $8.18 | +168.95% | 5 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $63 | $36.45 | +72.84% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $10 | $2.02 | +395.05% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $2 → $1 | $0.59 | +70.47% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $1.04 | +380.77% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $8 | $0.81 | +882.80% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $21.79 | +37.68% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $0.91 | +284.62% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $135.05 | +170.27% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $53.78 | -14.47% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $28 | $23.07 | +21.37% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.07 | +2,703.74% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $2.66 | +1,591.73% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $47.25 | -4.76% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $3.48 | +1,911.49% | 1 | Jul 14, 2017 |
Biomea Fusion
Oct 30, 2024
Maintains: Equal-Weight
Price Target: $9 → $11
Current: $6.53
Upside: +68.45%
Arcus Biosciences
Oct 25, 2024
Maintains: Overweight
Price Target: $25 → $29
Current: $15.70
Upside: +84.71%
Revolution Medicines
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $55.13
Upside: +8.83%
Relay Therapeutics
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $5.11
Upside: +233.01%
Syndax Pharmaceuticals
Aug 15, 2024
Maintains: Overweight
Price Target: $32 → $33
Current: $15.83
Upside: +108.46%
Exscientia
Aug 13, 2024
Downgrades: Equal-Weight
Price Target: $5
Current: $4.69
Upside: +6.61%
Immunocore Holdings
Aug 9, 2024
Maintains: Overweight
Price Target: $92 → $66
Current: $31.59
Upside: +108.93%
MacroGenics
Jul 31, 2024
Maintains: Overweight
Price Target: $9 → $8
Current: $3.57
Upside: +124.09%
Arvinas
Jul 31, 2024
Maintains: Overweight
Price Target: $60 → $48
Current: $22.48
Upside: +113.52%
Blueprint Medicines
Jul 29, 2024
Maintains: Equal-Weight
Price Target: $75 → $105
Current: $88.69
Upside: +18.39%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $22.92
Upside: +35.25%
Jun 7, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $10.80
Upside: +57.41%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $3.85
Upside: +237.66%
Apr 11, 2024
Downgrades: Equal-Weight
Price Target: $25
Current: $34.45
Upside: -27.43%
Mar 7, 2024
Maintains: Overweight
Price Target: $7 → $9
Current: $4.41
Upside: +104.08%
Feb 29, 2024
Maintains: Overweight
Price Target: $18 → $22
Current: $8.18
Upside: +168.95%
Feb 29, 2024
Maintains: Overweight
Price Target: $47 → $63
Current: $36.45
Upside: +72.84%
Feb 27, 2024
Maintains: Overweight
Price Target: $6 → $10
Current: $2.02
Upside: +395.05%
Aug 10, 2023
Maintains: Underweight
Price Target: $2 → $1
Current: $0.59
Upside: +70.47%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $1.04
Upside: +380.77%
Aug 5, 2022
Maintains: Overweight
Price Target: $14 → $8
Current: $0.81
Upside: +882.80%
Jul 28, 2022
Initiates: Overweight
Price Target: $30
Current: $21.79
Upside: +37.68%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $0.91
Upside: +284.62%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $135.05
Upside: +170.27%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $53.78
Upside: -14.47%
Mar 4, 2020
Initiates: Underweight
Price Target: $28
Current: $23.07
Upside: +21.37%
Mar 4, 2020
Initiates: Overweight
Price Target: $30
Current: $1.07
Upside: +2,703.74%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $2.66
Upside: +1,591.73%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $47.25
Upside: -4.76%
Jul 14, 2017
Initiates: Buy
Price Target: $70
Current: $3.48
Upside: +1,911.49%